NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ADMA. Investigation Details On October 9, 2024, ADMA Biologics disclosed the abrupt resignation of its independe ...

ADMA Biologics, Inc.’s (ADMA) is witnessing a phenomenal run this year. Its shares have surged a whopping 262.1% in the year so far against the industry’s decline of 2.1%.The stock has been consistently touching new highs in this timeframe, having recently hit a new 52-week high of $21.13 on Oct. 9.The stock has also outperformed the sector and the S&P 500 during the aforementioned period.ADMA Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchThe stupendous rally can be attributed ...

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

Core Viewpoint - ADMA Biologics, Inc. is under investigation for potential violations of federal securities laws following the unexpected resignation of its independent auditor, leading to a significant drop in its stock price [1]. Group 1: Company Overview - ADMA Biologics is a biopharmaceutical company that specializes in manufacturing, marketing, and developing specialty biologics aimed at treating immunodeficient patients and those at risk for infectious diseases [1]. Group 2: Recent Developments - On October 9, 2024, ADMA Biologics announced the surprise resignation of its independent outside auditor, CohnReznick LLP, which triggered a sharp decline in its stock price [1]. - The stock price of ADMA Biologics fell by more than 20% during trading on October 10, 2024, following the announcement [1]. Group 3: Legal Implications - Bleichmar Fonti & Auld LLP is investigating ADMA Biologics for potential legal actions related to the stock drop, encouraging affected investors to seek additional information and consider their legal options [2].

SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether ADMA Biologics, Inc. (NASDAQ: ADMA) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased ADMA Biologics securities? If you purchased securities and suffer ...

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

Core Viewpoint - October has historically been a volatile month for Wall Street, and this year is no exception, with volatility driven by various factors including better-than-expected jobs data, expectations of a gradual Fed rate cut, rising Treasury yields, geopolitical tensions, and the upcoming U.S. Presidential election [1] Group 1: Market Conditions - U.S. stock markets have experienced significant volatility since the beginning of October [1] - Factors contributing to this volatility include strong jobs data for September and expectations of a gradual rather than aggressive Fed rate cut [1] - The yield on the benchmark 10-Year Treasury Note has increased, adding to market uncertainty [1] - Geopolitical conflicts in the Middle East and the upcoming U.S. Presidential election are also influencing market dynamics [1] Group 2: Stock Performance - A selection of stocks has shown price strength amidst the volatility, particularly those on a recent bull run [1] - Five highlighted stocks include Atour Lifestyle Holdings Ltd. (ATAT), Vertiv Holdings Co. (VRT), Corcept Therapeutics Inc. (CORT), Qifu Technology Inc. (QFIN), and ADMA Biologics Inc. (ADMA) [1] Group 3: Stock Analysis - **Atour Lifestyle Holdings Ltd. (ATAT)**: Stock price increased by 39% in the past four weeks, with expected earnings growth of 32.6% for the current year and a 10.9% improvement in the Zacks Consensus Estimate over the last 60 days [4] - **Vertiv Holdings Co. (VRT)**: Stock price rose by 31.2% in the past four weeks, with an expected earnings growth rate of 45.8% for the current year and a 6.2% improvement in the Zacks Consensus Estimate over the last 90 days [5] - **Corcept Therapeutics Inc. (CORT)**: Stock price surged by 29.2% in the past four weeks, with an expected earnings growth rate of 19.2% for the current year and a 1.8% improvement in the Zacks Consensus Estimate over the last 30 days [6] - **Qifu Technology Inc. (QFIN)**: Stock price appreciated by 25% in the past four weeks, with expected earnings growth of 38% for the current year and a 2.8% improvement in the Zacks Consensus Estimate over the last 30 days [7] - **ADMA Biologics Inc. (ADMA)**: Stock price advanced by 20.2% in the past four weeks, with an expected earnings growth rate of 29.6% for next year and an 8.5% improvement in the Zacks Consensus Estimate over the last 60 days [8]

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 10, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ADMA Biologics, Inc. (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. ADMA Biologics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to ...

BOSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating ADMA Biologics, Inc. (Nasdaq: ADMA) for potential securities law violations. Investors who have lost money in their ADMA Biologics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/adma.  What is this all about? On October 10, 2024, shares of ADMA Biologics, Inc. fell nearly 20% following the Company's after-market announcement that its i ...

The most recent trading session ended with Adma Biologics (ADMA) standing at $20.33, reflecting a -1.91% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 0.71%. At the same time, the Dow added 1.03%, and the tech-heavy Nasdaq gained 0.6%.The the stock of infectious disease drug developer has risen by 19.84% in the past month, leading the Medical sector's loss of 3.33% and the S&P 500's gain of 6.41%.The upcoming earnings release of Adma Biologic ...